A small-molecule inhibitor of nuclear β-catenin activity can inhibit both the AR and β-catenin–signaling pathways in prostate cancer, and induce decreased binding of AR to its target genes sequences, as well as inhibit PCa growth in vivo [177]. Here, AR is linked to prostate cancer.